BioSpace News Archive

Drug Development

GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.

May 6, 2019
·
4 min read
Business

Welltower Expands Leadership Team in Investments

Welltower Inc. (NYSE: WELL) today announced that Ayesha Menon and Edward Cheung have joined the Company as Senior Vice Presidents of Investments.

May 6, 2019
·
3 min read
Business

TraceLink Achieves 44% Overall Revenue Growth for Q1 2019

Financial and company results for the first quarter of 2019

May 6, 2019
·
4 min read
Calliditas Therapeutics to Host Conference Call to Provide Business Update and 2019 Q1 Report

On May 8, 2019, at 07:00am CET, Calliditas Therapeutics (“Calliditas”) will publish its business update for the first quarter 2019.

May 6, 2019
·
2 min read
Biotech Beach

Regulus Therapeutics Announces Restructuring of Term Loan

Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022

May 6, 2019
·
4 min read
Genetown

Relapsing Remitting MS Patients Who Received Lemtrada® (alemtuzumab) Reported Improvements in Treatment Satisfaction and Health-Related Quality of Life in Clinical Studies

Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi’s Lemtrada® (alemtuzumab) experienced improvements in treatment satisfaction and health-related quality of life, according to investigational data from two clinical studies

May 6, 2019
·
13 min read
Drug Development

PharmaCyte Biotech Advances Manufacturing Process for Clinical Trial in Pancreatic Cancer

Advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer

May 6, 2019
·
5 min read
BioForest

Global CRISPR and CAS Gene Market to Surpass US$ 7,603.8 million by 2026

The global CRISPR and CAS gene Market was valued at US$ 1,388.1 million in 2017, and is projected to exhibit a CAGR of 20.8% during the forecast period (2018 – 2026).

May 6, 2019
·
3 min read
Genetown

Relapsing MS Patients Who Received Aubagio® (teriflunomide) Experienced a Reduced Risk of Relapse Regardless of Prior Treatment Status in a Post-Hoc Analysis

These results will be presented this week during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.

May 6, 2019
·
7 min read
Business

Skyhawk Therapeutics Announces Agreement with Takeda to Develop Novel Small Molecule RNA Splicing Modifiers for Neurodegenerative Diseases

Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases. In exchange Takeda will pay Skyhawk an upfront payment, future milestone payments and royalties.

May 6, 2019
·
1 min read